MAGED4 and renal cell carcinoma: Now MAGE-D4 has been expressed in a range of tumors such as oral squamous cell carcinoma (36, 37), non-small cell lung cancer (38, 39), esophageal squamous cell carcinoma (11, 40), hepatocellular carcinoma (9), renal cell carcinoma (12), colorectal carcinoma (10), and glioma (41), etc. Our previous studies showed that MAGE-D4 was highly expressed in glioma tissues and was immunogenic in glioma patients (13, 42), implying a potential for MAGE-D4 for glioma immunotherapy.